From a clinical point of view, the differential sensitivity of glioma stem cells and non-stem glioma cells revealed in this study has profound implications for how MDM2 inhibitors should be used in the treatment of glioblastoma. The gene discussed is MDM2; the disease is central nervous system cancer.